LOS ANGELES — Using low-dose tissue plasminogen activator (tPA; alteplase) delivered by surgical catheter to remove clots of pooled blood from the brain's ventricles after intraventricular hemorrhage ...

During an ischemic stroke, blood vessels in the brain are blocked or narrowed. During a hemorrhagic stroke, there's bleeding into the brain. The first treatment for stroke is to potentially offer a ...

The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours ...

Compared with the standard clot-busting medication alteplase, the newer clot-buster known as tenecteplase may offer a safe, effective and simpler way to treat ischemic (clot-caused) stroke in mobile ...

For people with ischemic stroke, treatment with the clot-busting drug tenecteplase is associated with a slightly higher likelihood of an excellent recovery and reduced disability three months later ...

Greater thrombus permeability, a more distal thrombus location, and longer time to assessment are factors associated with outcomes of recanalization of an arterial occlusion in patients with acute ...

Less than one-third of acute stroke patients treated with intravenous tissue plasminogen activator (tPA) receive the clot-busting drug within 60 minutes of their hospital arrival, according to ...

The use of a potentially lifesaving, clot-busting drug -- called tissue plasminogen activator (tPA) -- to treat patients with ischemic stroke nearly doubled between 2003 and 2011, according to a large ...

Thrombolytic therapy defines a group of medications that can dissolve blood clots. Healthcare professionals may administer them to treat a medical emergency, such as a heart attack or stroke. The ...

In a randomized clinical trial, giving the clot-busting medication alteplase up to 24 hours after stroke symptoms first appeared increased the odds of better recovery by 50% compared to those who ...